These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31623671)

  • 1. Molecular mutations as a possible factor for determining extent of thyroid surgery.
    Krasner JR; Alyouha N; Pusztaszeri M; Forest VI; Hier MP; Avior G; Payne RJ
    J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):51. PubMed ID: 31623671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules.
    Musholt TJ; Fottner C; Weber MM; Eichhorn W; Pohlenz J; Musholt PB; Springer E; Schad A
    World J Surg; 2010 Nov; 34(11):2595-603. PubMed ID: 20652698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
    Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
    Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
    Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Limitation of Fine-Needle Aspiration (FNA) on Indeterminate Thyroid Nodules Can Be Partially Overcome by Preoperative Molecular Analysis: Assessment of RET/PTC1 Rearrangement in BRAF and RAS Wild-Type Routine Air-Dried FNA Specimens.
    Ko YS; Hwang TS; Kim JY; Choi YL; Lee SE; Han HS; Kim WS; Kim SK; Park KS
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
    Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative cytology with molecular analysis to help guide surgery for pediatric thyroid nodules.
    Buryk MA; Monaco SE; Witchel SF; Mehta DK; Gurtunca N; Nikiforov YE; Simons JP
    Int J Pediatr Otorhinolaryngol; 2013 Oct; 77(10):1697-700. PubMed ID: 23993207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
    Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
    Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review.
    Hier J; Avior G; Pusztaszeri M; Krasner JR; Alyouha N; Forest VI; Hier MP; Mlynarek A; Richardson K; Sadeghi N; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2021 Apr; 50(1):29. PubMed ID: 33910629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules.
    Fu G; Chazen RS; Monteiro E; Vescan A; Freeman JL; Witterick IJ; MacMillan C
    JAMA Netw Open; 2023 Jul; 6(7):e2323500. PubMed ID: 37505499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF(V600E) Mutation, RET/PTC1 and PAX8-PPAR Gamma Rearrangements in Follicular Epithelium Derived Thyroid Lesions - Institutional Experience and Literature Review.
    Şahpaz A; Önal B; Yeşilyurt A; Han Ü; Delibaşı T
    Balkan Med J; 2015 Apr; 32(2):156-66. PubMed ID: 26167339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.
    Rossi M; Buratto M; Tagliati F; Rossi R; Lupo S; Trasforini G; Lanza G; Franceschetti P; Bruni S; Degli Uberti E; Zatelli MC
    Thyroid; 2015 Feb; 25(2):221-8. PubMed ID: 25333496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
    Silver JA; Bogatchenko M; Pusztaszeri M; Forest VI; Hier MP; Yang JW; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2021 Nov; 50(1):63. PubMed ID: 34742355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid Cancer.
    Fu G; Chazen RS; MacMillan C; Witterick IJ
    JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical role of BRAF V600E mutation testing in thyroid nodules].
    Wan H; Zhang B; Wang Y; Xiao T; Guo H; Liu W; Yan D; Xu Z; Tang P
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jun; 49(6):468-72. PubMed ID: 25241863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.